Missing In Action: China’s Best Shot In Ebola Vaccine Race
Executive Summary
As the Congo grapples with the latest outbreak of Ebola, China has approved its first domestically developed vaccine in record time, hailing it a national innovation champion. But as the World Health Organization starts vaccinations in Africa, can China make the cut and compete with global players including Merck & Co?
You may also be interested in...
Ebola Outbreak In DR Congo: Where Are The Vaccines In Development?
Following reports of another Ebola outbreak in Africa, Scrip explores the pipeline of clinical-stage vaccines and how the companies developing immunizations are approaching the most recent cases of the viral hemorrhagic disease.
Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Asia Executives On The Move: Sanofi's Global R&D Head Moves To Innovent
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Need a specific report? 1000+ reports available
Buy Reports